. eGFR was not associated with the presence of a minor or major depressive episode. Results were similar when we assessed associations with depressive symptoms or clinically relevant depressive symptoms (PHQ-9 score !10).
Conclusions. Albuminuria was associated with depressive symptoms and depressive episodes, even at levels of UAE that do not fulfil the CKD criteria. Future longitudinal studies should examine the direction of this association and whether albuminuria could serve as a biomarker to identify individuals at risk of depression.
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I N T R O D U C T I O N
Depression is common in individuals with chronic kidney disease (CKD) (prevalence $25%) [1] , in whom it is associated with increased morbidity [2] and mortality [3] . The frequent occurrence of cerebral small vessel disease (cSVD) in CKD [4] may be one explanation for the high prevalence of depression in CKD. According to the vascular depression hypothesis [5, 6] , cSVD may lead to depression through disruption of neuronal circuits involved in mood regulation. Furthermore, neurotoxic effects of the uraemic milieu [7] and the presence of comorbidities [8] such as obesity, type 2 diabetes mellitus (T2DM) and hypertension may be involved.
However, data on the association of albuminuria, which together with reduced estimated glomerular filtration rate (eGFR) defines CKD [9] , with depression are scarce and conflicting [10, 11] . Albuminuria may indicate generalized endothelial dysfunction [12, 13] , which in the brain may cause cSVD [14] . Therefore, albuminuria may be a biomarker of vascular disease processes involved in depression. Indeed, albuminuria was borderline statistically significantly associated with depressive symptoms in individuals with DM without cardiovascular disease (CVD) [10] . In contrast, it was not associated in individuals with DM with CVD [10] or in a CKD population [11] . However, in both studies, assessment of depressive symptoms instead of a diagnosis of minor or major depressive episode may have led to misclassification of somatic symptoms of (comorbid) disease as depressive symptoms [1] .
In addition, it is not clear when in the course from normal kidney function to CKD the associations of eGFR and albuminuria with depression appear. Literature on the associations of eGFR and albuminuria with CVD [15, 16] suggests that both may already be associated with adverse health outcomes at levels that do not fulfil the CKD criteria. In this regard, the results of previous studies suggest that eGFR may not be associated with depression until moderately to severely reduced [11, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , whereas data on this topic are lacking for albuminuria.
In view of the above, we examined whether albuminuria and eGFR were, independent of each other, associated with both self-reported depressive symptoms and an interview-based diagnosis of minor or major depressive episode in a populationbased cohort without substantial CKD.
M A T E R I A L S A N D M E T H O D S

The Maastricht Study population and design
We used data from the Maastricht Study, an observational prospective population-based cohort study [30] . Eligible for participation were all individuals between 40 and 75 years of age living in the southern part of The Netherlands. Recruitment was stratified according to known T2DM, with an oversampling of individuals with T2DM, for reasons of efficiency. The present report includes cross-sectional data from the first 3451 participants, who completed the baseline survey between November 2010 and September 2013. The examinations of each participant were performed within a time window of 3 months. The study was approved by the institutional medical ethical committee (NL31329.068.10) and the Minister of Health, Welfare and Sports of the Netherlands (Permit 131 088-10 5234-PG) and was conducted in accordance with the Declaration of Helsinki. All participants gave written informed consent.
Kidney function
To assess urinary albumin excretion (UAE), participants were requested to collect two 24-h urine collections (Supplemental Methods). UAE was based on the average of two (available in 91.5% of the participants) 24-h urine collections. GFR was estimated with the Chronic Kidney Disease Epidemiology Collaboration equation based on the combination of serum creatinine and serum cystatin C (eGFR crcys ) (Supplemental Methods) [31] .
Depressive symptoms
Depressive symptoms were assessed with a validated Dutch version of the 9-item Patient Health Questionnaire (PHQ-9) [32] . The PHQ-9 is a self-administered questionnaire based on the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for a major depressive episode. It comprises nine items rated on a 4-point scale, ranging from 0 ('not at all') to 3 ('nearly every day'). Response options are used to calculate a continuous total depressive symptom score ranging from 0 (no symptoms) to 27 (all symptoms present nearly every day). When one or two items were missing, the total score was calculated as 9 Â (total points/9 À number of missing items) and rounded to the nearest integer. As a continuous variable, scores 0-9 represent no, 10-14 represent moderate, 15-19 represent moderately severe and 20-27 represent severe depression [33] . A predefined cut-off score of !10 was considered to indicate clinically relevant depressive symptoms [32] .
In addition, we calculated affective (i.e. anhedonia, depressed mood, feeling of worthlessness, thoughts of death) and somatic (i.e. fatigue, appetite changes, sleep difficulties, concentration difficulties, psychomotor agitation/retardation) subscores, based on a confirmatory factor analysis conducted previously [34] .
Minor and major depressive episode
The Mini-International Neuropsychiatric Interview (MINI) [35] was used to assess the presence of a minor or major depressive episode in the preceding 2 weeks according to the DSM-IV criteria. A major depressive episode was diagnosed if participants had at least one core symptom (i.e. depressed mood or anhedonia) and at least four other symptoms of depression (i.e. significant weight change or change in appetite, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy, guilt or worthlessness, diminished ability to think or concentrate or indecisiveness and suicidal thoughts or plans). Persons suffering from one core symptom and one to three other symptoms were classified as having a minor depressive episode.
Potential confounders
We assessed glucose metabolism status, body mass index, waist circumference, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, office blood pressure, 24-h average ambulatory blood pressure, medication use, smoking behaviour, alcohol consumption, prevalent CVD, educational level, marital status, medical history, physical activity and cognitive performance, as described previously [30, 36] . Glucose metabolism was classified according to the World Health Organization 2006 criteria [37] into normal glucose metabolism, impaired fasting glucose, impaired glucose tolerance and DM. Participants with DM and participants using glucose-lowering medication were considered as having T2DM if they had no (self-reported) type 1 or other specific type of DM. For this study, impaired fasting glucose and impaired glucose tolerance were combined into prediabetes. Body mass index was calculated by dividing weight by height 2 [38, 39] . Participants who were married or in a civil partnership or who cohabited were classified as married/living with spouse. Participants were classified as having comorbid disease other than T2DM and CVD if they reported being diagnosed with non-skin cancer, inflammatory bowel disease, inflammatory respiratory disease and/or Parkinson's disease (28 participants with missing data were classified as having no comorbid disease). A modified version of the Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire [40] was used to assess weekly total and moderate to vigorous physical activity. The Mini-Mental State Examination (MMSE) was used as a measure of global cognitive performance [41] . In addition, we assessed information processing speed as the standardized composite score of the Stroop Color Word Test Parts I and II [42] , the Concept Shifting Test Parts A and B [43] and the Letter-Digit Substitution Test [44] , as this cognitive domain has been associated with albuminuria in the present cohort [36] .
Statistical analyses
All analyses were performed with SPSS Statistics Version 22.0 (IBM, Armonk, NY, USA) unless stated otherwise. Population characteristics were presented stratified by the presence of clinically relevant depressive symptoms and by the presence of a major depressive episode. Associations of albuminuria and eGFR crcys with depressive symptoms were evaluated with negative binomial regression analyses because of the extremely skewed distribution of PHQ-9 scores [45] [46] . eGFR crcys was entered as a continuous variable and expressed per 10 mL/ min/1.73 m 2 lower eGFR crcys . The regression coefficients were exponentiated to obtain the ratio of the depressive symptom score per 10 mL/min/1.73 m 2 lower eGFR crcys or when compared with UAE <15 mg/24 h.
Associations of albuminuria and eGFR crcys with clinically relevant depressive symptoms, major depressive episode and minor or major depressive episode were evaluated with multivariable logistic regression analyses.
All regression analyses were adjusted for potential confounders as follows: model 1: unadjusted model; model 2: age, sex, educational level, marital status, comorbid disease, glucose metabolism status; model 3: model 2 þ waist circumference, total:HDL cholesterol, triglycerides, the use of lipid-modifying medication, smoking behaviour, alcohol consumption; model 4: model 3 þ eGFR crcys or UAE; model 5a: model 4 þ office systolic pressure, the use of antihypertensive medication, prevalent CVD; model 5b: model 5a but with replacement of office systolic pressure by 24-h average ambulatory systolic pressure. Blood pressure and prevalent CVD were added separately, as these variables may be confounders and/or intermediates in the above associations.
Several additional analyses were performed to explore the robustness of our results. First, we restricted the analyses to participants with UAE 300 mg/24 h and to the subpopulation with two valid urine collections. Second, we additionally adjusted for total or moderate to vigorous physical activity. Third, we additionally adjusted for cognitive performance, expressed as either the MMSE score or information processing speed. Fourth, we assessed associations of albuminuria and eGFR crcys with affective and somatic subscores of the PHQ-9 to explore whether any associations with the total PHQ-9 score were driven by somatic complaints in individuals with higher UAE or lower eGFR crcys . Fifth, we included antidepressant use in our definitions of major depressive episode and minor or major depressive episode.
R E S U L T S
Characteristics of the study population 
based on 2872 participants (PHQ-9 subpopulation) and the analyses on the MINI on 3083 participants (MINI subpopulation). Table 1 shows the characteristics of the MINI subpopulation. Due to oversampling, 846 (27.4%) participants had T2DM. In total, 122 (4.3%) participants had clinically relevant depressive symptoms, 112 (3.6%) had a major depressive episode and 54 (1.8%) had a minor depressive episode. Of those with a major or minor depressive episode, 33 (29.5%) and 4 (7.4%) used an antidepressant, respectively. Characteristics of the PHQ-9 subpopulation (Table 1) were similar.
In general, participants with a major depressive episode were slightly younger, slightly more often women, less educated, more often lived alone, more often had T2DM or other comorbid disease, had a worse CVD risk profile and had a lower information processing speed.
Albuminuria, depressive symptoms and depressive episodes
The median UAE was 6.7 [interquartile range (IQR) 4.0-11.9] mg/24 h. UAE was <15 mg/24 h in 2502 (81.2%) participants, 15-<30 mg/24 h in 317 (10.3%) participants and !30 mg/24 h in 264 (8.6%) participants ( Table 1) .
The median depressive symptom score was 2 (IQR 0-4), 2 (IQR 0-5) and 2 (IQR 1-5) in individuals with UAE <15 mg/ 24 h, 15-<30 mg/24 h and !30 mg/24 h, respectively. After adjustment, and when compared with participants with UAE <15 mg/24 h, participants with UAE 15-<30 mg/24 h and !30 mg/24 h had a higher depressive symptom score and more often had a depressive episode, regardless of their definitions ( 
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After adjustment, eGFR crcys was not associated with the depressive symptom score or the presence of a depressive episode, regardless of their definitions (Table 3 , models 5a and 5b).
Additional analyses
Results were not materially altered when the analyses were restricted to individuals with UAE 300 mg/24 h or to The columns 'Study population' and 'Major depressive episode (MINI)' present the characteristics of the MINI subpopulation (n ¼ 3083), whereas the column 'Clinically relevant depressive symptoms (PHQ-9)' presents the characteristics of the PHQ-9 subpopulation (n ¼ 2872). For the MINI subpopulation available in n ¼ 2704 (total physical activity), n ¼ 2703 (moderate to vigorous physical activity), n ¼ 3082 participants (BMI categories), n ¼ 2731 participants (24 h average ambulatory systolic and diastolic pressure), n ¼ 2842 (PHQ-9 score), n ¼ 2842 (clinically relevant depressive symptoms (PHQ-9 ! 10)), n ¼ 3081 (MMSE score) and n ¼ 3029 (information processing speed) participants. For the PHQ-9 subpopulation available in n ¼ 2686 (total physical activity), n ¼ 2685 (moderate to vigorous physical activity), n ¼ 2871 (BMI categories), n ¼ 2559 (24 h average ambulatory systolic and diastolic pressure), n ¼ 2842 (major depressive episode and major or minor depressive episode), n ¼ 2865 (MMSE score) and n ¼ 2818 (information processing speed) participants.
c P-values for the comparison of participants with and without clinically relevant depressive symptoms and of participants with and without a major depressive episode were calculated with the independent Student t-test for normally distributed variables, the Mann-Whitney U test for non-normally distributed variables and the v 2 test for categorical variables. Ratios represent the ratio of the depressive symptom score when compared with participants with UAE <15 mg/24 h. ORs represent the odds of having clinically relevant depressive symptoms, a major depressive episode and a minor or major depressive episode, respectively, relative to the odds in participants with UAE <15 mg/24 h. Model 1: unadjusted model; model 2: model 1 þ age, sex, educational level, marital status, comorbid disease, glucose metabolism status; model 3: model 2 þ waist circumference, total:HDL cholesterol ratio, triglycerides, the use of lipid-modifying medication, smoking behaviour, alcohol consumption; model 4: model 3 þ eGFR crcys ; model 5a: model 4 þ office systolic pressure, the use of antihypertensive medication, prevalent cardiovascular disease; model 5b: similar to model 5a but adjusted for ambulatory systolic pressure instead of office systolic pressure (missing in n ¼ 313 participants for PHQ-9 and n ¼ 352 for major depressive episode and minor or major depressive episode). (Table 4) or when results were additionally adjusted for total or moderate to vigorous physical activity, the MMSE score or information processing speed (Tables 4 and 5 ). Analyses of the associations of albuminuria and eGFR crcys with somatic and affective subscores of the PHQ-9 showed that albuminuria was associated with both a higher affective and somatic symptom score, although the association of UAE !30 mg/24 h with affective symptoms was not statistically significant after adjustment for lifestyle factors and CVD risk factors. eGFR crcys was associated with neither subscore (data not shown). When we included antidepressant use in our definition of major depressive episode and minor or major depressive episode, UAE 15-<30 mg/24 h and !30 mg/ 24 h remained associated with both major depressive episode and minor or major depressive episode, although the strength of the associations was attenuated and the association of UAE !30 mg/24 h with major depressive episode was no longer statistically significant after adjustment for lifestyle factors and CVD risk factors. eGFR crcys was not associated with the alternative definitions of depressive episode (data not shown). Ratios represent the ratio of the depressive symptom score per 10 mL/min/1.73 m 2 lower eGFR. ORs represent the relative difference in the odds of having clinically relevant depressive symptoms, a major depressive episode and a minor or major depressive episode, respectively, per 10 mL/min/1.73 m 2 lower eGFR. Model 1: unadjusted model; model 2: model 1 þ age, sex, educational level, marital status, comorbid disease, glucose metabolism status; model 3: model 2 þ waist circumference, total:HDL cholesterol ratio, triglycerides, the use of lipidmodifying medication, smoking behavior, alcohol consumption; model 4: model 3 þ UAE (categorical); model 5a: model 4 þ office systolic pressure, the use of antihypertensive medication, prevalent cardiovascular disease; model 5b: similar to model 5a but adjusted for ambulatory systolic pressure instead of office systolic pressure (missing in n ¼ 313 participants for PHQ-9 and n ¼ 352 for major depressive episode and minor or major depressive episode). 
To our knowledge, this study is the first to examine whether albuminuria and eGFR are, independent of each other, associated with depression in a population-based setting. It had two main findings. First, albuminuria was associated with both selfreported depressive symptoms and minor or major depressive episode after adjustment for demographic variables, comorbidity, lifestyle factors and CVD risk factors (including eGFR), even at levels of UAE that do not fulfil the CKD criteria. Second, eGFR was neither associated with depressive symptoms nor with minor or major depressive episode in this cohort without substantial CKD. The results of this study contrast with a study in individuals with CKD [11] , which showed no independent association between albuminuria and depressive symptoms. However, its participants were selected for the presence of CKD based on eGFR values [11] , whereas most participants in the present population-based study had normal or mildly reduced eGFR. The higher burden of symptoms of CKD and comorbid disease [11] may have reduced the contrast between participants with higher and lower albuminuria levels. In another study, albuminuria was only borderline statistically significantly associated with depressive symptoms in individuals with DM without CVD but not with CVD [10] . However, a large proportion had poor glycaemic control, and its complications may have been classified erroneously as depressive symptoms.
Generalized endothelial dysfunction may explain the association between albuminuria and depression. According to this concept, microvascular endothelial dysfunction in the kidney causes albuminuria [12, 13] , whereas in the brain it causes cSVD [14] . According to the vascular depression hypothesis [5, 6] , the latter may lead to depression through disruption of neuronal circuits involved in mood regulation in fronto-limbic brain areas [5, 6] . Indeed, albuminuria has been associated with magnetic resonance imaging findings of cSVD [47] and cSVD has been associated with incident depressive symptoms [48, 49] . In addition, studies showing an association of (plasma) biomarkers of endothelial dysfunction with depressive symptoms [50] and minor or major depressive episode [51] indirectly support this view. However, we cannot rule out reverse causation. Indeed, depressive symptoms [52] and major depressive episode [2, 53] have been associated with a higher risk of end-stage renal disease [2, 52, 53] . This may also be true for albuminuria, e.g. through the adoption of an unhealthy lifestyle and poor treatment adherence [54, 55] . However, adiposity, smoking behavior, alcohol consumption and physical activity did not explain the reported associations.
The non-linear association of albuminuria with depression contrasts with the reported linear associations of (plasma) biomarkers of endothelial dysfunction with depressive symptoms [50] and minor or major depressive episode [51] . Selective nonparticipation of individuals with depression and UAE !30 mg/ 24 h due to a higher comorbid disease burden in these individuals [46, 56] (i.e. incidence-prevalence bias [57] ) could account for the non-linearity. Furthermore, the small number of cases with depression limited power and the 95% CIs do not exclude a linear association.
Importantly, the association of albuminuria with depression is not likely due to misclassification of somatic symptoms of comorbid disease, as albuminuria was associated with both selfreported depressive symptoms and an interview-based diagnosis of minor or major depressive episode. Furthermore, we adjusted for comorbid disease and albuminuria was related to affective as well as somatic depressive symptoms.
A lack of power probably explains why the association of UAE !30 mg/24 h with major depressive episode was borderline statistically significant, whereas it was statistically significant for minor and major depressive episode combined. Minor and major depressive episodes are part of a continuum of mood disorders, differing only in the number of depressive symptoms [58] . Indeed, lower quality of life, more disability, higher health care consumption and, although not consistently, increased mortality in individuals with a minor depressive episode [58] point to its clinical importance.
In contrast, the inclusion of individuals who only had an early onset major depressive episode may have attenuated the association between albuminuria and depression when antidepressant use was included in our definition of depression. Early and late-onset depression may have different causes [59] and cerebrovascular disease is more likely involved in late-onset depression [60] . In addition, antidepressants may have been prescribed for indications other than depression, e.g. neuropathic pain, leading to misclassification of depression status. In this study without substantial CKD, eGFR was not associated with depression. However, this study was underpowered to comment on the association of eGFR <60 mL/min/1.73 m 2 with depression. Nevertheless, when combined with the results of other studies on the association of eGFR with depression [11, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , eGFR seems not to be associated with depression until it is moderately toseverely reduced.
An important strength of this study was the assessment of albuminuria with 24-h urine collections and the assessment of eGFR based on creatinine and cystatin C. Another strength was the evaluation of an interview-based diagnosis of DSM-IV minor or major depressive episode, which reduced the risk of misclassification of symptoms of somatic diseases as depressive symptoms [1] . In addition, the elaborate clinical characterization of the study participants allowed for extensive adjustment for potential confounders, including 24-h average ambulatory blood pressure. However, some limitations of this study should be considered. First, the cross-sectional design limited causal inferences. Second, even though we adjusted for an extensive series of potential confounders, we cannot fully exclude residual confounding. For example, we had no data on polymorphisms of the renin-angiotensin system [60, 61] or activity of the hypothalamic-pituitary-adrenal axis [62, 63] . Third, the exclusion of participants with missing data may have led to an underestimation of the examined associations if those with a higher UAE or reduced eGFR and concomitant (severe) depression were selectively excluded. Fourth, we had no data on the use of nonpharmacological treatments of depression, which may have been applied successfully in some participants and could have led to an underestimation of the association of eGFR and albuminuria with depression. Fifth, the study population was recruited from a single region in The Netherlands and primarily consisted of Caucasian individuals of European descent (98.6%), which may limit generalizability to other ethnic and racial groups.
In conclusion, albuminuria was associated with depressive symptoms and minor or major depressive episode, even at levels of UAE that do not fulfil the CKD criteria. Future longitudinal studies should examine the direction of this association and whether albuminuria could serve as a biomarker to identify individuals at risk of depression. 
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